Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359484 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL17792581 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL15250722 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL18081881 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL16247696 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL15494174 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL18293150 | 0.93 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL16549790 | 0.91 | P2RY6 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL15258090 | 0.87 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 | |
| SCHEMBL15725392 | 0.86 | P2RY2 (0.36) | P2RY2P2RY6P2RY4TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221891-B2 | In vivo production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | P2RY2 3346/4885P2RY6 3365/4885P2RY4 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.